Mode
Text Size
Log in / Sign up
Phase 2 N=73 Randomized Double-blind Treatment

Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients

Indigestion

Enrolled (actual)
73
Serious AEs
0.0%
Results posted
Nov 2019
Primary outcome: Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Esomeprazole (Drug); Placebo (Other)
Age
Adult · 18+ yrs
Sex
All
Sponsor
University of Kansas Medical Center
Primary completion
Jan 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms
71; 34; 82; 56
SECONDARY
Satisfactory Relief of Non-ulcer Dyspepsia Symptoms as Time Gastric pH Remained > 4.0 Within 24 Hours
1170; 905; 1050; 762

Summary

Inhibition of gastric acid is the key to satisfactory relief of symptoms with esomeprazole in NUD patients

Eligibility Criteria

Inclusion criteria

A. Males and females of age 18-55. B. A diagnosis of epigastric pain/discomfort (located in the upper abdomen) rated by the patient as moderate to severe in intensity (on a four-point categorical scale), which has been present at least 3 times per week for 12 weeks, unrelated to exercise.

C. Patients may have other symptoms of NUD including heartburn, regurgitation, bloating (abdominal distension), early satiety (feeling of fullness), belching (burping), or nausea; however, the dominant symptom must be epigastric pain/discomfort.

D. Capable of and willing to give informed consent and comply with all study requirements.

Exclusion criteria

A. H. pylori positive serology. B. Regular use of NSAIDs or more than 100 mg of aspirin. C. Patients requiring chronic treatment with any medication inducing GI symptoms (e.g., certain antibiotics, codeine, etc.).

D. History or presence of endoscopic/radiological evidence of esophagitis. E. History or presence of chronic gastric or duodenal ulcer. F. History or presence of duodenal erosions. G. History or previous upper GI surgery. H. Presence of concomitant symptoms of irritable bowel syndrome (IBS) as assessed by three or more of the Manning or Rome criteria.

I. History or presence of other known organic disease that might explain the dyspepsia symptoms (e.g., symptomatic gallstones).

J. Pregnancy or lactation. K. Inadequate contraception. L. Regular consumption of greater than 2 fluid ounces of beverage alcohol (corresponding to 2 cocktails or 40 fluid ounces of beer or 16 fluid ounces of wine) per day.

M. History of substance abuse. N. Unwillingness or expected inability to tolerate absence of antisecretory medications (antacids, H2 receptor antagonists or Proton pump inhibitors (PPIs) or other GI pharmacotherapy for a period of time of study protocol (16 weeks maximum).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00222131). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search